NasdaqCM:AGEN

Stock Analysis Report

Executive Summary

Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer.

Snowflake

Fundamentals

Concerning outlook with worrying balance sheet.

Share Price & News

How has Agenus's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-0.4%

AGEN

1.7%

US Biotechs

0.5%

US Market


1 Year Return

33.7%

AGEN

-7.2%

US Biotechs

6.8%

US Market

Return vs Industry: AGEN exceeded the US Biotechs industry which returned -7.2% over the past year.

Return vs Market: AGEN exceeded the US Market which returned 6.8% over the past year.


Shareholder returns

AGENIndustryMarket
7 Day-0.4%1.7%0.5%
30 Day-13.5%-3.4%-0.8%
90 Day7.4%-1.3%-0.9%
1 Year33.7%33.7%-6.3%-7.2%9.2%6.8%
3 Year-54.4%-54.4%14.8%10.9%45.6%36.2%
5 Year-12.7%-12.7%-2.3%-7.0%63.2%45.4%

Price Volatility Vs. Market

How volatile is Agenus's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Agenus undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Agenus is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Agenus has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

Future Growth

How is Agenus forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

-6.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AGEN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AGEN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AGEN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: AGEN's revenue (18.3% per year) is forecast to grow faster than the US market (7.2% per year).

High Growth Revenue: AGEN's revenue (18.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if AGEN's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Agenus performed over the past 5 years?

-19.9%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: AGEN is unprofitable, and losses have increased over the past 5 years at a rate of -19.9% per year.

Accelerating Growth: Unable to compare AGEN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AGEN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (78.4%).


Return on Equity

High ROE: AGEN's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets

ROA vs Industry: AGEN is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: AGEN is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Agenus's financial position?


Financial Position Analysis

Short Term Liabilities: AGEN has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: AGEN has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: AGEN has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: AGEN's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: AGEN has a low level of unsold assets or inventory.

Debt Coverage by Assets: AGEN has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AGEN has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: AGEN has less than a year of cash runway if free cash flow continues to grow at historical rates of 8.1% each year.


Next Steps

Dividend

What is Agenus's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.0%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate AGEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate AGEN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if AGEN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AGEN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AGEN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Agenus's salary, the management and board of directors tenure and is there insider trading?

1.5yrs

Average management tenure


CEO

Garo Armen (66yo)

25.8yrs

Tenure

US$2,567,842

Compensation

Dr. Garo H. Armen, Ph.D., founded Agenus Inc. in 1994 and has been its Chief Executive Officer since 1994. Dr. Armen serves as an Executive Chairman of Agenus Inc. He has been an Executive Director of Agen ...


CEO Compensation Analysis

Compensation vs. Market: Garo's total compensation ($USD2.57M) is about average for companies of similar size in the US market ($USD1.80M).

Compensation vs Earnings: Garo's compensation has been consistent with company performance over the past year.


Management Age and Tenure

1.5yrs

Average Tenure

60yo

Average Age

Experienced Management: AGEN's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.


Board Age and Tenure

10.8yrs

Average Tenure

61yo

Average Age

Experienced Board: AGEN's board of directors are seasoned and experienced ( 10.8 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Garo Armen (66yo)

    Founder

    • Tenure: 25.8yrs
    • Compensation: US$2.57m
  • Alex Duncan (57yo)

    CTO & Head of Research

    • Tenure: 3.8yrs
    • Compensation: US$833.26k
  • Christine Klaskin (53yo)

    VP of Finance

    • Tenure: 0.2yrs
    • Compensation: US$497.48k
  • Ozer Baysal (63yo)

    Chief Commercial Officer & Head of HR

    • Tenure: 2.3yrs
    • Compensation: US$461.73k
  • Jennifer Buell

    Chief Operating Officer

    • Tenure: 0.9yrs
    • Compensation: US$986.47k
  • John Castle

    Head of Translational Medicine & Bioinformatics

    • Tenure: 1.8yrs
  • Evan Kearns

    VP, General Counsel & Secretary

    • Tenure: 1.3yrs
  • Julie DeSander

    Vice President of Business Development & Alliance Management

    • Tenure: 1.8yrs
  • Paulo Moreira

    Global Head of Clinical Operations

    • Tenure: 0.6yrs
  • Don Vidic

    VP & Head of Commercial

    • Tenure: 0.3yrs

Board Members

  • Garo Armen (66yo)

    Founder

    • Tenure: 25.8yrs
    • Compensation: US$2.57m
  • Ulf Wiinberg (61yo)

    Independent Director

    • Tenure: 3.4yrs
    • Compensation: US$195.08k
  • Wadih Jordan (84yo)

    Independent Director

    • Tenure: 16.6yrs
    • Compensation: US$113.70k
  • Tim Wright (61yo)

    Lead Director

    • Tenure: 10.8yrs
    • Compensation: US$218.70k
  • Brian Corvese (61yo)

    Independent Director

    • Tenure: 12.6yrs
    • Compensation: US$257.58k
  • Allison Jeynes-Ellis (53yo)

    Director

    • Tenure: 0.9yrs
    • Compensation: US$167.78k

Company Information

Agenus Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Agenus Inc.
  • Ticker: AGEN
  • Exchange: NasdaqCM
  • Founded: 1994
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$359.760m
  • Shares outstanding: 137.31m
  • Website: https://agenusbio.com

Number of Employees


Location

  • Agenus Inc.
  • 3 Forbes Road
  • Lexington
  • Massachusetts
  • 2421
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AGENNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDFeb 2000
AJ81DB (Deutsche Boerse AG)YesCommon StockDEEURFeb 2000

Biography

Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an a ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/20 23:31
End of Day Share Price2019/10/18 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.